Alyona Mazhnaya1, Anna Meteliuk2, Tetiana Barnard2, Alexei Zelenev3, Sergii Filippovych2, Frederick L Altice4. 1. ICF Alliance for Public Health in Ukraine, 9th Floor, Building 10A, 5 Dilova (Dymytrova) Str., Kyiv 03150, Ukraine; Johns Hopkins Bloomberg School of Public Health, Department of Health, Behavior and Society, 624 N Broadway, Baltimore, MD 21205, USA. Electronic address: hmazhnaya@gmail.com. 2. ICF Alliance for Public Health in Ukraine, 9th Floor, Building 10A, 5 Dilova (Dymytrova) Str., Kyiv 03150, Ukraine. 3. Yale University School of Medicine, Section of Infectious Diseases, AIDS Program, P.O. Box 208022, New Haven, CT 06520-8022, USA. 4. Yale University School of Medicine, Section of Infectious Diseases, AIDS Program, P.O. Box 208022, New Haven, CT 06520-8022, USA; Yale University School of Public Health, Division of Epidemiology of Microbial Diseases, 60 College Street, P.O. Box 208034, New Haven, CT 06520-8034, USA.
Abstract
BACKGROUND: HCV prevalence estimates among people who inject drugs (PWID) in Ukraine is high (60-90%), yet barriers to HCV treatment and care remain substantial including limited access to direct acting antiviral (DAA) medications. A feasibility scale-up project implemented HCV treatment in community-based settings to improve access to DAA treatment for key populations in this context. METHODS: Using program-level data and verified medical records, we describe the development, implementation processes and outcomes for HCV treatment for PWID and other risks groups. Most participants (76%) received a combination of sofosbuvir, pegylated interferon, and ribavirin for 12 weeks. Treatment enrollment started in June 2015; the first two waves are reported. Data on demographics, HIV characteristics, HCV genotype and RNA levels, including sustained virologic response (SVR) were obtained from verified medical records. We used logistic regression to examine the independent correlates of achieving a SVR. RESULTS: The project was implemented in 19 healthcare institutions from 16 regions of Ukraine, mainly within AIDS specialty centers. Our analytical sample included 1126 participants who were mostly men (73%) and the majority were HIV co-infected (79%). Treatment retention was 97.7%; the proportions of participants who achieved SVR for the overall sample and for those with complete data (N=1029) were 86.2% (95% CI 84.08-88.19%) and 94.3% (95% CI 92.8-95.7%) respectively. The analysis of data restricted to only those with SVR data available showed that PWID who were currently injecting had comparable SVR rates (89.2%, 95% CI 81.5-94.5%) to PWID not injecting (94.4%, 95% CI 92.4-96.1), PWID on methadone (94.4%, 95%CI 92.4-96.1), and 'other' risk groups (95.2%, 95% CI 91.3-97.7). Independent factors associated with achieving a SVR were female sex (AOR: 3.44, 95% CI 1.45-8.14), HCV genotype 3 (AOR: 4.57, 95% CI 1.97-10.59) compared to genotype 1. SVR rates in PWID actively injecting did not differ significantly from any other group. CONCLUSION: Both patient-level and structural factors influence HCV treatment scale-up in Ukraine, but patient-level outcomes confirm high levels of achieving SVR in PWID, irrespective of injection and treatment status.
BACKGROUND:HCV prevalence estimates among people who inject drugs (PWID) in Ukraine is high (60-90%), yet barriers to HCV treatment and care remain substantial including limited access to direct acting antiviral (DAA) medications. A feasibility scale-up project implemented HCV treatment in community-based settings to improve access to DAA treatment for key populations in this context. METHODS: Using program-level data and verified medical records, we describe the development, implementation processes and outcomes for HCV treatment for PWID and other risks groups. Most participants (76%) received a combination of sofosbuvir, pegylated interferon, and ribavirin for 12 weeks. Treatment enrollment started in June 2015; the first two waves are reported. Data on demographics, HIV characteristics, HCV genotype and RNA levels, including sustained virologic response (SVR) were obtained from verified medical records. We used logistic regression to examine the independent correlates of achieving a SVR. RESULTS: The project was implemented in 19 healthcare institutions from 16 regions of Ukraine, mainly within AIDS specialty centers. Our analytical sample included 1126 participants who were mostly men (73%) and the majority were HIV co-infected (79%). Treatment retention was 97.7%; the proportions of participants who achieved SVR for the overall sample and for those with complete data (N=1029) were 86.2% (95% CI 84.08-88.19%) and 94.3% (95% CI 92.8-95.7%) respectively. The analysis of data restricted to only those with SVR data available showed that PWID who were currently injecting had comparable SVR rates (89.2%, 95% CI 81.5-94.5%) to PWID not injecting (94.4%, 95% CI 92.4-96.1), PWID on methadone (94.4%, 95%CI 92.4-96.1), and 'other' risk groups (95.2%, 95% CI 91.3-97.7). Independent factors associated with achieving a SVR were female sex (AOR: 3.44, 95% CI 1.45-8.14), HCV genotype 3 (AOR: 4.57, 95% CI 1.97-10.59) compared to genotype 1. SVR rates in PWID actively injecting did not differ significantly from any other group. CONCLUSION: Both patient-level and structural factors influence HCV treatment scale-up in Ukraine, but patient-level outcomes confirm high levels of achieving SVR in PWID, irrespective of injection and treatment status.
Authors: Kate Mason; Zoë Dodd; Mary Guyton; Paula Tookey; Bernadette Lettner; John Matelski; Sanjeev Sockalingam; Jason Altenberg; Jeff Powis Journal: Int J Drug Policy Date: 2017-06-12
Authors: Jason Grebely; Gregory J Dore; Stefan Zeuzem; Richard J Aspinall; Raymond Fox; Lingling Han; John McNally; Anu Osinusi; Diana M Brainard; G Mani Subramanian; Macky Natha; Graham R Foster; Alessandra Mangia; Mark Sulkowski; Jordan J Feld Journal: Clin Infect Dis Date: 2016-08-23 Impact factor: 9.079
Authors: Rozalyn Milne; Morgan Price; Bruce Wallace; Anne Drost; Irene Haigh-Gidora; Frank A Nezil; Chris Fraser Journal: Int J Drug Policy Date: 2015-07-21
Authors: Jeffrey D Stanaway; Abraham D Flaxman; Mohsen Naghavi; Christina Fitzmaurice; Theo Vos; Ibrahim Abubakar; Laith J Abu-Raddad; Reza Assadi; Neeraj Bhala; Benjamin Cowie; Mohammad H Forouzanfour; Justina Groeger; Khayriyyah Mohd Hanafiah; Kathryn H Jacobsen; Spencer L James; Jennifer MacLachlan; Reza Malekzadeh; Natasha K Martin; Ali A Mokdad; Ali H Mokdad; Christopher J L Murray; Dietrich Plass; Saleem Rana; David B Rein; Jan Hendrik Richardus; Juan Sanabria; Mete Saylan; Saeid Shahraz; Samuel So; Vasiliy V Vlassov; Elisabete Weiderpass; Steven T Wiersma; Mustafa Younis; Chuanhua Yu; Maysaa El Sayed Zaki; Graham S Cooke Journal: Lancet Date: 2016-07-07 Impact factor: 79.321
Authors: Olena Iakunchykova; Anna Meteliuk; Alexei Zelenev; Alyona Mazhnaya; Melissa Tracy; Frederick L Altice Journal: Int J Drug Policy Date: 2018-04-12
Authors: David Ortiz-Paredes; Afia Amoako; Taline Ekmekjian; Kim Engler; Bertrand Lebouché; Marina B Klein Journal: Front Public Health Date: 2022-06-24
Authors: Matthew J Akiyama; Lindsey R Riback; Mercy Nyakowa; Helgar Musyoki; John A Lizcano; Abbe Muller; Chenshu Zhang; Josephine G Walker; Jack Stone; Peter Vickerman; Peter Cherutich; Ann E Kurth Journal: J Viral Hepat Date: 2022-03-15 Impact factor: 3.517
Authors: Anishaa Sivakumar; Lynn Madden; Elizabeth DiDomizio; Anthony Eller; Merceditas Villanueva; Frederick L Altice Journal: Int J Drug Policy Date: 2021-12-20